Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert I Nicholson

Showing results (51-60 of 77) with videos related to

Pageof 8
Sort By:
Breast Cancer Research : BCR|March 15, 2011
Fulvestrant-induced expression of ErbB3 and ErbB4 receptors sensitizes oestrogen receptor-positive breast cancer cells to heregulin β1Iain R Hutcheson, Lindy Goddard, Denise Barrow, et al.
Endocrine-Related Cancer|January 30, 2007
Inductive mechanisms limiting response to anti-epidermal growth factor receptor therapyIain R Hutcheson, Janice M Knowlden, Helen E Jones, et al.
The Prostate|May 7, 2002
Multiple responses to EGF receptor activation and their abrogation by a specific EGF receptor tyrosine kinase inhibitorMaureen E Harper, Lindy Goddard, Eve Glynne-Jones, et al.
Breast Cancer Research : BCR|September 1, 2018
Correction to: Heregulin β1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cellsIain R Hutcheson, Janice M Knowlden, Steve E Hiscox, et al.
Breast Cancer Research : BCR|August 10, 2007
Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cellsIain R Hutcheson, Janice M Knowlden, Steve E Hiscox, et al.
Breast Cancer Research : BCR|January 25, 2014
Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitroNicola J Jordan, Carol M Dutkowski, Denise Barrow, et al.
Cancer Research|June 3, 2006
Elevated expression of mitogen-activated protein kinase phosphatase 3 in breast tumors: a mechanism of tamoxifen resistanceYukun Cui, Irma Parra, Mao Zhang, et al.
Histopathology|September 13, 2011
A review of the biological and clinical characteristics of luminal-like oestrogen receptor-positive breast cancerHany O Habashy, Desmond G Powe, Tarek M Abdel-Fatah, et al.
Endocrinology|February 15, 2003
Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cellsJanice M Knowlden, Iain R Hutcheson, Helen E Jones, et al.
The Journal of Pathology|May 14, 2004
Expression of luminal and basal cytokeratins in human breast carcinomaDalia M Abd El-Rehim, Sarah E Pinder, Claire E Paish, et al.
Pageof 8

Showing results (51-60 of 77) with videos related to

Sort By:
Pageof 8
Breast Cancer Research : BCR|March 15, 2011
Fulvestrant-induced expression of ErbB3 and ErbB4 receptors sensitizes oestrogen receptor-positive breast cancer cells to heregulin β1Iain R Hutcheson, Lindy Goddard, Denise Barrow, et al.
Endocrine-Related Cancer|January 30, 2007
Inductive mechanisms limiting response to anti-epidermal growth factor receptor therapyIain R Hutcheson, Janice M Knowlden, Helen E Jones, et al.
The Prostate|May 7, 2002
Multiple responses to EGF receptor activation and their abrogation by a specific EGF receptor tyrosine kinase inhibitorMaureen E Harper, Lindy Goddard, Eve Glynne-Jones, et al.
Breast Cancer Research : BCR|September 1, 2018
Correction to: Heregulin β1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cellsIain R Hutcheson, Janice M Knowlden, Steve E Hiscox, et al.
Breast Cancer Research : BCR|August 10, 2007
Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cellsIain R Hutcheson, Janice M Knowlden, Steve E Hiscox, et al.
Breast Cancer Research : BCR|January 25, 2014
Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitroNicola J Jordan, Carol M Dutkowski, Denise Barrow, et al.
Cancer Research|June 3, 2006
Elevated expression of mitogen-activated protein kinase phosphatase 3 in breast tumors: a mechanism of tamoxifen resistanceYukun Cui, Irma Parra, Mao Zhang, et al.
Histopathology|September 13, 2011
A review of the biological and clinical characteristics of luminal-like oestrogen receptor-positive breast cancerHany O Habashy, Desmond G Powe, Tarek M Abdel-Fatah, et al.
Endocrinology|February 15, 2003
Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cellsJanice M Knowlden, Iain R Hutcheson, Helen E Jones, et al.
The Journal of Pathology|May 14, 2004
Expression of luminal and basal cytokeratins in human breast carcinomaDalia M Abd El-Rehim, Sarah E Pinder, Claire E Paish, et al.
Pageof 8